Overview

Trial Targeting Gut Bacterial Androgen Production to Reverse Therapeutic Resistance to Abiraterone in Patients With Metastatic Prostate Cancer

Status:
RECRUITING
Trial end date:
2032-03-30
Target enrollment:
Participant gender:
Summary
To determine if dexamethasone or dexamethasone plus metronidazole restore sensitivity to abiraterone for the treatment of metastatic prostate cancer.
Phase:
PHASE2
Details
Lead Sponsor:
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Collaborators:
Prostate Cancer Foundation
United States Department of Defense
Treatments:
Abiraterone Acetate
Dexamethasone
Metronidazole